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Abstract 
A chemical survey of 58 marine samples obtained from three sites around 
Tauranga New Zealand was undertaken in an effort to identify new metabolites. 
MTT assays using HeLa and P388 cell lines were carried out to determine if any of 
the samples contained bioactive compounds. 
 
For each sample, a crude extract was obtained and analysed by Liquid 
Chromatography Mass Spectrometry (LCMS). The chromatogram traces were 
examined and fives samples containing potential metabolites of interest were 
chosen for further investigation. Of the five samples two were identified from 
preliminary taxonomic analysis as Lyngbya sp. (cyanobacterium) and Cliona 
celata (a sponge). The compound targeted in Lyngbya sp. was thought to 
potentially be a new peptide and the Cliona celata compounds contained 
bromine atoms. These two samples were extracted in bulk and fractionated by 
reversed phase and size exclusion chromatography. From the mass spectral data 
and the taxonomy there were no identified samples on the MarinLit database. 
The separation yielded several fractions and these were analysed by LCMS to 
identify which ones contained the targeted compounds. Nuclear magnetic 
resonance (NMR) spectroscopy and tandem mass spectrometry was then used 
on the most concentrated (targeted compound) fractions to get more structural 
information. NMR spectroscopy of Cliona celata was found contain many 
impurities and the target compounds concentrations were not sufficient enough 
to give any structural information. The compound from Lyngbya sp. appeared to 
be a fatty acid.  The sterol composition of Cliona celata was also analysed by gas 
chromatography mass spectrometry (GCMS). The three other samples analysed 
in more detail were Aplidium sp. (RI 2-13), Alcyonaria sp. (RI 2-14) and Ircinia sp. 
(RI 2-17). These samples were fractionated by small scale chromatography and 
then subjected to tandem mass spectrometry with some structural features 
being identified. 
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All samples from the chemical survey were tested against the HeLa and P388 cell 
lines using the MTT assay. After inconclusive results from initial tests, the 
method was modified to give more consistent results. Even with the 
modifications to the method, there were still inconsistencies in the results. Only 
one sample, the brown alga Xiphophora sp. gave an expected trend of decreasing 
cell metabolism with increasing sample concentration which would indicate 
cytotoxic activity. The experiment would need to be repeated in independent 
tests to confirm the result.
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1 Natural Products Overview 
1.1 What are natural products and why are they of interest? 
Living species produce two types of compounds, primary metabolites and 
secondary metabolites. Primary metabolites sustain cell metabolism and support 
the functioning of the organism.1 These molecules generally only have a 
biological effect within the cell or organism producing them. Secondary 
metabolites (which are also referred to as natural products) tend to have 
bioactive effects on a range of species rather than just the one that produces 
them and often their purpose is not readily apparent. 2, 5 Once their range of 
bioactivity is known the compounds can then be utilised for research and 
commercial applications. 
 
Generally the role of natural products is to assist in the protection and 
maintenance of homeostasis of the organism.3 To humans they are largely of 
interest due to their technological applications. Natural products have been used 
as flavours, fragrances and pharmaceuticals along with many more rich and 
varied applications.4 By isolating and solving the structures of these molecules 
scientists have been able to learn about their biosynthesis and have applied 
combined knowledge of the structural information with therapeutic 
biochemistry to develop pharmaceuticals.5 For example the discovery of 
penicillin in 1929 led to its large scale manufacture as an antibiotic.6 
 
Natural Product structures have already been “screened” by evolution for their 
usefulness and can act as a starting point for drug development.7 Also by 
isolating and studying these molecules information about their larger ecological 
role can be obtained.8 The need to find new and useful substances for continued 
medical development is one important aspect natural products play in modern 
life. A major problem with current antibacterial drugs is that bacteria gradually 
become more resistant to treatments. Natural products have already proven 
their effectiveness and have contributed well to this effort, with two thirds of 
clinical antibacterial drugs we use today either being directly sourced natural 
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compounds or altered semi-synthetic versions of them.9 However, current 
antibiotics being relied upon are based on only a handful of frameworks and 
their synthetic derivations. Therefore, varied compounds usually found in diverse 
natural sources are needed.9 
 
1.2 Why Study marine samples? 
Marine samples are a rich but largely unexplored (in part because marine 
organisms have been harder to collect and identify) source of biodiversity.10 As a 
chemical environment the ocean is considered to be quite constant but in fact 
nutrient levels in the ocean vary greatly as do trace metals and vitamins.4 On 
account of the differing environment both chemically and biologically it follows 
that marine species will produce different types of natural products from 
terrestrial species.4 This has already been proven with many marine natural 
product structures that have no precedent from the terrestrial environment and 
show new toxicological properties.3 The peptides and proteins are also of 
interest because their high site specificity can help determine biological 
functions.11   
 
The collection of biologically varied samples of marine species is relatively easy 
as a large amount of marine biodiversity is found in areas along the shoreline. 
Estimations have put these areas along with deep sea ocean vents as the most 
species rich areas in the world.12 These concentrations of species in one 
environment drives competition and particularly in the sessile organisms forces 
chemical adaptations to evolve that act as feeding deterrents or inhibit the 
growth of other species.12 For example, the cone snail Conus purpurascens uses a 
mixture of peptides (conotoxins) injected via a harpoon like structure that 
disrupts the voltage gated ion channels and immobilises its prey.13 Some species 
also produce feeding deterrents. For example, the green alga 
Pseudochlorodesmis furcellata produces two diterpenoids that reduce predation 
by herbivorous fish.14 Modern advances in technology such as SCUBA gear has 
enabled access to new areas and facilitated extensive sampling of marine life.15 
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Accessing this new diverse biota increases the chances of finding new molecular 
frameworks. When the function of a molecule is understood such as finding a 
selectively reactive functional group or how a specific framework is utilised, it 
can provide a platform for new drugs to be synthesised.5 
 
The journal Natural Product Reports has annually reviewed and documented the 
recently discovered compounds of a wide variety of marine phyla. Some 
examples representative of the natural products found in species within six phyla 
discussed in Natural Products Reports are presented here to provide an overview 
of the diversity and application of marine natural products.16, 17  
 
1.2.1 Cnidaria 
Cnidaria is a phylum of marine invertebrates containing a diverse range of over 
11,000 species.18 They are primitive multi-celled organisms with a basic nervous 
system and have an important role in large ecosystems such as coral reefs.18, 19 
The hard coral Scleractinia forms the basis of most coral reefs.20 Cnidarians have 
two known main methods of defences; nematocysts which are stinging 
structures and chemicals.21 A study of 18 cnidarians found that the species using 
both defensive methods to live in habitats with high predation pressure such as 
coral reefs.21 There have already been compounds with potential 
chemotherapeutic uses discovered in this phylum, mainly with anti-tumour 
activity but also compounds with anti-bacterial, anti-HIV (Human 
immunodeficiency virus) and anti-inflammatory properties as well as molecules 
to support nervous system health. Several different families of natural products 
have been isolated from cnidarians such as prostanoids, steroids and 
polyketides. Of more interest are the terpenoids which are found to have the 
most biotechnological potential of the compounds isolated from cnidarians.18 
The diterpenoid blumiolide C (1) isolated from the cnidarian soft coral Xenia 
blumi showed strong cytotoxic effect against the P388 (mouse leukaemia) and 
HT-29 (human colon adenocarcinoma) cell lines.18  
 
4 
 
 
 
Seven other related diterpenoids (2-8) as well as blumiolide C (1) were isolated 
from Xenia blumi and were subjected to bioassay guided fractionation. Their 
structures were elucidated by 1- and 2-D proton and carbon nuclear magnetic 
resonance (NMR) spectroscopy. Blumiolide C (1) was very cytotoxic to both cell 
lines with ED50 (effective dose to inhibit 50% of the population) values of 0.5 
µg/mL and 0.2 µg/mL against the P388 and HT-29 cell lines respectively.22 
 
In the nervous systems of cnidarians there are many peptides that are important 
for neurotransmission and some that are neurohormones.19 Isolation and 
characterisation of these peptides can lead to information about their functions, 
the roles they play in the nervous system and their biosynthesis. The separation 
of neuropeptides can be difficult as in extracts there can be several other 
(3) (4) (5) 
(6)
  Datyloene-B 
(8)
)  Datyloene-B 
(1)
  Datyloene-B 
(2)
  Datyloene-B 
(7)
  Datyloene-B 
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proteins.19 A Japanese group, in conjunction with German and American 
colleagues, fractionated a cnidarian extract by HPLC and analysed a 
chromatogram containing over 10,000 peaks. From this exhaustive process, 
several C-terminally amidated peptides were isolated.19 
 
Cnidarians have also been shown to produce many severe toxins.23 Two 
cnidarians Stichodactyla helianthus and Bunodosoma granulifera were collected 
from the sea around Cuba and their crude extracts injected into mice. After 
neurotoxic symptoms were observed, another experiment was carried out to 
test the extracts inhibitory effects of the extracts on the activity of 
cholinesterase. It was concluded that the crude extracts contained 
cholinesterase inhibitors that were able to pass through the blood brain barrier. 
The crude material was fractionated by gel filtration and reversed phase 
chromatography with two inhibitors being isolated, BgK a 37 amino acid peptide 
from Bunodosoma granulifera and ShK, a 35 amino acid peptide from 
Stichodactyla helianthus. Both peptides blocked potassium channels and each 
contained three disulphide bridges. The importance of knowing the details about 
these structures can assist in the analysis of similar peptides which have almost 
the same amino acid numbers but several differences in activity. In the case of 
potassium channel blockers, BgK and ShK block different subtypes of the 
channels but due to their similar amino acid number, it is likely a structural 
difference causing the selectivity.24 
 
A study from Brazil tested eight cnidarian species to look for natural products for 
use as therapeutic agents against the protozoan diseases Leishmaniasis and 
Chagas disease.25, 26 Current treatments for both diseases are expensive, have 
severe side effects and resistance to them is increasing. Current Chagas 
chemotherapy can cause vomiting and skin disorders. 27 Leishmaniasis has 
partially become resistant to the pentavalent antimonial class of drugs, a 
treatment used for sixty years.28 Of the nine crude extracts that were screened, 
four species: Carijoa riisei, Heterogorgia uatumani, Leptogorgia punicea, and 
Macrorhynchia philippina were found to have antiprotozoal properties. Based on 
(7) (2)   Datyloene-B 
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the IC50 values of the four species, the steroid 18-acetoxipregna-1, 4, 20-trien-3-
one (9) from the octocoral C. riisei was further investigated and found to have 
good selectivity. Its cytotoxic effects targeted Leishmania sp. with much more 
potency than macrophage cells.25 
 
 
1.2.2 Molluscs 
With over 80,000 species divided into six diverse classes Mollusca is another 
phylum from which a variety of useful and interesting natural products have 
been procured. The molluscs’ body structure consists of three parts: a head, foot 
and visceral mass containing the organs. Most molluscs are also protected by a 
shell.29 
 
 Molluscs that are not protected by a shell however have adapted chemical and 
other defences for survival. For example, the subclass Opistobranchia does not 
grow a shell and produces several toxic anti-feedants to deter predators.30 Even 
the molluscs whose shells protects them from predatory danger still filter feed 
which can lead to the uptake of viruses and bacteria.31 In response to this species 
such as Cerstoderma edule and Ostrea edulis produce anti-viral and anti-bacterial 
compounds.32 
 
Two polypropionates with methylated variants named Fusaripyrones A (10 and 
11) and B (11 and 12) have been isolated and characterised from the 
opistobranch mollusc Haminoea fusari.33
(9) 
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The electrospray ionisation mass spectra contained the pseudo-molecular ions 
(M+Na+) of these compounds and combined with various types of NMR 
spectroscopy, enabled the structures to be elucidated. On account of the 
unstable nature of these molecules, they were methylated which allowed them 
to be purified for analysis. The underivatised compounds were isolated later. 
These structures may assist with solving the evolutionary relationships of 
Haminoea as there are other related species which produce molecules with 
similar structures and therefore probably share at least some of the same genes 
driving that biosynthetic pathway.33  
 
The natural product ziconotide (13) was isolated from the cone snail Conus 
magnus which uses it  as venom to hunt prey.34, 35 
 
 
Ziconotide’s structure is a 25 amino acid chain with three disulphide bridges to 
form four asymmetrical loops. The rigid structure of the molecule allows it to 
bind selectively to N-type calcium channels.  Its mechanism of action is to block 
10 R=H        
11 R=CH3 
11 R=H        
12 R=CH3 
(13) 
Cys=Cysteine 
Lys=Lysine 
Gly=Glycine 
Ala=Alanine 
Ser=Serine 
Arg=Arginine 
Leu=Leucine 
Met=Methionine 
Tyr=Tyrosine 
Asp=Aspartic acid 
Thr=Threonine 
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the release of N-type calcium ion channels that facilitate neuronal excitability 
and neurotransmission. It has advantages over current opiate based medication 
as it does not have the potential to form a mental or physical addiction and there 
has been no observed respiratory depression.36 Ziconotide (marketed under the 
name Prialt) has been approved for clinical use in both the U.S.A and Europe, it is 
1000 times more potent than morphine and therefore a much more effective 
treatment for neuropathic pain.35 
 
The sea hare Aplysia dactylomela has been found to be a rich source of novel 
compounds, particularly terpenoids. Aplysia feeds on red algae containing a large 
number of terpenoids, some of which it sequesters for its own use and can 
chemically alter to reduce their toxicity.37, 38 Aplysia dactylomela has been a 
source of natural products over a long period of time, Dactoxylene-B (14) is one 
of three sesquiterpene ethers that were isolated from a sample in 1974,39 a 
diterpene (15) was reported from a sample off the Canary Islands from another 
sample of A. dactylomela in 198340 and Aplysiols A (16) and B (17) in 2007.41  
   
 
(15) 
 
(14) 
(16) 
(17) 
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The unnamed diterpene (15) structure was solved by X-ray crystallography.39, 40 
 
Three new chamigrene compounds one unnamed (18), Acetyldeschloroelatol 
(19) and Acetylelatol (20) were isolated from a sample of Aplysia dactylomela. 
Some known related compounds were also isolated (21-24). 
 
 
 
 
The crude extracts were separated by LH-20 chromatography and then high 
performance liquid chromatography (HPLC) used to obtain pure samples. 
Electron impact mass spectrometry (EIMS) spectrum data allowed the 
identifications of the halogens in the molecules. The structures were solved by 
combining this information with high resolution EIMS along with proton and 
carbon NMR spectroscopic techniques. The compounds were tested against two 
cancer cell lines (HeLa and Hep-2) and Vero (monkey kidney cells) to see if they 
had any bioactivity. The acetyl derived compound acetylelatol showed much less 
cytotoxicity than elatol (22) indicating under these conditions acetylation 
reduces toxicity of elatol. It has been proposed that Aplysia dactylomela 
performs this structural change itself after it ingests the algae containing elatol.38 
 
(23) R=Ac 
(24) R=H 
 
(20) R=Ac 
(22) R=H 
 (19) R=Ac 
 (21) R=H 
(18) 
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Four more chamigrene sesquiterpenoids (25-28) were isolated from Aplysia 
dactylomela and tested against HL-60 and THP-1 leukaemia cells.  
 
 
Extensive 1- and 2-D NMR spectroscopy combined with mass spectral data were 
used to solve the structures. Sesquiterpene (28) showed some cytotoxic activity 
against both THP-1 and HL-60 cell lines with IC50 values of 152 and 102 µmol L
-1 
respectively. By comparing (28) to the non-cytotoxic dactylone (a related 
analogue), it was determined that the replacement of the carbonyl group and 
double bond in dactylone with the diol structure of (28) plays an important role 
in the cytotoxicity.37 
 
1.2.3 Tunicates 
 
Tunicates (Ascidians), also known as sea squirts, are a group of sedentary filter 
feeding animals that consist of around 3000 species and have been found to 
contain many interesting natural products.42 Tunicates spread their populations 
by releasing swimming larvae that eventually settle onto hard surfaces, where 
they undergo metamorphosis to their adult form and develop a protective 
cellulose layer. Once they have attached themselves to a surface they can 
asexually reproduce to establish colonies.43 There have been over 1000 
(25) (26) 
(27) (28) 
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compounds isolated from tunicates with some in clinical use, others used as anti-
tumour leads and some acting as multidrug resistance blockers.44 
 
Five new ecdysteroids, hyousterone A-D (29-32) and dialusterol B (33) were 
isolated from a sample of an Antarctic tunicate Synoicum adareanum.  
 
 
The sample was extracted in methanol: dichloromethane (1:1) and HPLC was 
used to separate the compounds. Their structures were elucidated using a 
variety of techniques including HRESIMS and 1- and 2-D NMR spectroscopy. The 
hyousterones structures (29-32) are very similar differing only by the α- or β-
position of the hydroxyl group or a hydrogen atom substitution. The 
hyousterones B (30) and D (32) with β-hydroxyl groups and dialusterol B (33) 
showed little cytotoxicity but the hyousterones with α-hydroxyl groups (A and C 
29, 32) showed significant cytotoxicity. Hyousterones A (29) and C (32) had IC50 
values of 10.7 and 3.7 µmol/L respectively. The cytotoxicity assays were carried 
out against the cell lines HCT-116 (colon), H-125M (lung), L1210 (leukaemia) and 
CFU-GM (bone marrow) to see if any of the compounds had antitumour 
selectivity.45, 46 
 
One of the first tunicate natural products that had promise as a potential drug 
was Didemnin B (34) which was isolated from Trididemnum solidium in 1981.47 
(29) R1=α-OH R2=H  
(30) R1=β-OH R2=H 
(31) R1=α-OH R2=OH 
(32) R1=β-OH R2=OH 
(33) R1=R2=H     
 
2  1 
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After showing cytotoxic and antiviral properties, it was the first marine 
anticancer compound to enter Phase One and Two clinical trials. These trials 
were stopped due to anaphylaxis and neuromuscular side effects being 
observed.47 However the precedent was set and the potential of marine natural 
products as a source of pharmaceuticals had been established. After this, 
structurally similar compounds were tested for their antitumour potency and 
Aplidin which was isolated from Aplidium albicans showed similar antitumour 
activity to Didemnin B.47, 48 
 
 
(34) 
(35) 
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Aplidine (35) is a structural analogue of Didemnin B with a pyruvyl group at the 
N-lactyl side chain. It kills cells in a variety of ways, including two different 
mechanisms to induce apoptosis and inhibit receptor proteins. The structures of 
secondary metabolites are sometimes altered with the intention to change their 
properties and tailor them to be more suitable for drug use. During the synthesis 
of aplidine, modifications were made to keep it active for longer before being 
metabolised by enzymes.47 If Didemnin B (34) and Aplidine (35) are found to be 
suitable drug candidates, they may be limited by supply, as collection and 
aquaculture of the source organisms is difficult. Currently they are being 
produced by a multistep synthesis which may not be viable for large scale 
production.48 
 
1.2.4 Algae 
Algae are photosynthetic organisms with tens of thousands of species that can 
be either unicellular or multicellular.49 Their diversity and the extreme and 
changeable environment they live in means that they have adapted various 
chemical solutions by way of natural products to survive. In terms of a source of 
natural products beyond that of experimental work, algae can generally be 
grown quickly and easily to produce larger quantities of the compound(s) of 
interest.49 
 
 
The red alga Botrycladia leptopoda was collected near Karachi and the 
compound 3-formylindole (36) was extracted. One of the fractions eluted from 
chromatography of the extract contained a crystalline compound. After 
structural elucidation by 1H and 13C NMR and mass spectrometry it was 
determined to be 3-Formylindole (36).50 The molecule is a basic indole structure 
with an aldehyde side chain at carbon three on the pyrrole ring.  
(36) 
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Interestingly 3-formylindole was also found in the plant species Murraya exotica 
potentially indicating a link in the chemoevolutionary history of both species.51 
 
Another natural product found in both algae and terrestrial plants is loliolide 
(37).  
 
 
One study on thirteen species of algae found that they all contained loliolide (37) 
with other studies finding it in the plants Lolium perenne (ryegrass) and Salvia 
divinorum.52-54 Identification of loliolide both quantitatively and qualitatively in 
the algae species was done by comparing extracts run through GC-MS to a 
calibration curve generated from known concentrations of loliolide. Of the 
thirteen algae species, seven were red, five brown and one green. This marked 
the first time loliolide had been found in a species of green algae.54 
 
1.2.5 Sponges (Porifera) 
Sponges are sessile, filter-feeding animals with most species inhabiting the 
marine environment. They are essentially an assemblage of cells, forming no 
organs and with few cell specialisations.55 Some sponges with soft bodies are 
internally supported by a skeleton of calcium carbonate, silica or spongin.55 The 
pores (ostia) of the sponge intake water where it moves through the central 
cavity and out the osculum. During this process, the hairs of the collar cells 
(which maintain water flow through the sponge) trap any food contained in the 
water.55 There are over 8000 species of sponges, varying greatly in size and 
shape from tubes only an inch long to large bulbs. In 2005, over 5000 different 
compounds had been isolated from 500 species of sponges.55  
 
(37) 
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Care must be taken when analysing other marine organisms as their natural 
products may be sourced from sponges (or anything else lower in the food 
chain). For example, the red sponge Latrunculia magnifica produces a toxin 
(latrunculin) as a feeding deterrent that causes fish to immediately move away 
from it.56 It is eaten by a nudibranch (sea slug) that sequesters this toxin as its 
own feeding deterrent.55 Analysis of the nudibranch might conclude that it 
produces the toxin when actually it is synthesised by the sponge. Another two 
more proactive ways that marine sponges utilise their natural products is to 
inhibit the growth of other marine species and to release compounds to stop 
fouling organisms from settling on and potentially overgrowing the sponge.56 The 
sponge Siphonodictyon coralliphagum uses the compound siphonodictidin (38) 
to inhibit corals from growing around its osculum.56 
 
 
Aplysina fistularis releases aerothionin (39) into the sea surrounding it to stop 
fouling organisms from growing on and potentially smothering the sponge.56 
 
Sponges have remained almost identical morphologically since the Superior 
Cambrian 509 million years ago and are the simplest multicellular life forms on 
earth.57 On account of their limited complexity and their evolutionary age, 
sponges have had a long time to diversify and develop a wide variety of chemical 
survival solutions. These chemical defences allow sponges to deter predators, 
gain space in overgrown environments and protect themselves from infection.  
 
Natural products isolated from sponges have wide applications as treatments for 
a variety of viral diseases, cancers and inflammatory ailments. There is still much 
(38) 
(39) 
16 
 
to learn about how these compounds work at the biochemical level but the 
general mechanisms by which they inhibit the spread of many diseases are 
understood. This understanding allows for drugs to be developed to selectively 
attack specific targets.58 
 
Many of these natural products exhibit cytotoxic or inhibitory effects indicating 
potential medicinal benefits and some are antifouling agents which slow the 
growth of organisms on the surface they are applied to.3 A study of the sponges 
Spongia and Ircinia revealed that they contain fourteen compounds with varying 
levels of antiprotozoal properties, measured by bioassaying and obtaining IC50 
values. The structures of these molecules were determined by 1- and 2-D NMR 
spectroscopic techniques.59 The usefulness of chemicals with these properties is 
to kill protozoan species such as Plasmodium falciparum which causes Malaria. 
There is a need for new chemotherapeutic agents to combat this and other 
protozoan caused diseases. The current chemotherapeutics used were mostly 
discovered in the 1950s before marine natural products research was common. 
The treatments also have unwanted side effects and parasitic protozoa are 
developing resistance.60 
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Species from the genus Cliona, a sponge which grows in massive colonies on hard 
substrates have been examined from different areas around the world for their 
natural products.61 Storniamides A-D (40-43), a group of pyrrole alkaloids were 
isolated from an unknown Cliona species found on the coast of Punta Verda, 
Argentina.61, 62  
 
 
 
 
 
The crude extract was separated into hexane and methanol: water (9:1) 
partitions. From bioassay, the bioactive compounds were seen to be in the 
methanol/water layer and this was further fractionated and pure compounds 
obtained by HPLC. By using high resolution fast atom bombardment mass 
spectrometry (HRFABMS) and many different kinds of 1- and 2-D NMR 
spectroscopic techniques, the structures of all four compounds were solved. The 
HRFABMS gave molecular formulae and indicated that the molecules were very 
similar, differing only in the number of oxygen atoms. Initially the structure of 
storniamide A was solved to give the major structure which the other 
storniamides were determined from. Analysis of FABMS fragmentation enabled 
determination of which substituent groups were place on what rings and NMR 
spectroscopy was used to confirm the structural analogues. The location of the 
hydroxyl groups was solved by FABMS and COSY and localised correlation 
spectroscopy (LCOSY) and confirmed by COrrelation through LOng range 
Coupling (COLOC) spectra. FABMS gave information on the hydroxyl groups 
(40) R1=OH R2=R3=H 
(41) R1= R3=OH R2=H 
(42) R1=H R2=R3=OH 
(43) R1=R2= R3=OH 
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(from R1, R2 and R3) locations on the structure.  For stormiamide A (40), a 135 Da 
loss was seen twice indicating that both hydrogen atoms are on the enamide 
aromatics. Storniamide B (41) showed both 135 and 151 Da losses from the 
molecular ion, indicating one enamide aromatic ring has a hydrogen atom 
attached and the other a hydroxyl group attached. This in contrast to 
Storniamide C which only shows two consecutive 151 Da losses, indicating both 
hydroxyl groups are on the enamide aromatic rings. Storniamide D (43)  shows 
the same losses as C (42) but from the molecular formula, all three of its 
substituents are hydroxyl groups.61 
 
All of the storniamides showed antibiotic activity against Staphylococcus aureus 
and Micrococcus luteus. 61 An attempt to synthesise storniamide A resulted in 
only a partial synthesis, giving a nonamethyl ether analogue (44) with no 
cytotoxic effect.62 However this compound did have an interesting effect on 
some human colon cancer multidrug resistant cell lines, reversing their drug 
resistance and making them vulnerable to vinblastine and doxorubicin 
treatments.63 
 
 
A sample of the sponge Cliona celata was collected from Barkley Sound off 
Vancouver Island. The sample was extracted in ethanol then the concentrated 
extract partitioned between ethyl acetate and water. The extract had antibiotic 
properties when tested against Staphylococcus aureus. Subsequent testing that 
showed the antibiotic activity was in the ethyl acetate partition which contained 
(44) 
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also clionamide (45). Normal phase, size exclusion and reversed phase HPLC 
were all used to try to purify the crude extract but they did not result in effective 
separation. After using 1H-, 13C-NMR, MS and IR spectroscopy, the structure of 
the derivatised tetracetyl clionamide (46) was elucidated.  
 
Part of the structure is a brominated indole found in some marine organisms and 
the N-vinyl amide group was of chemical interest due to the rarity of it at the 
time of the discovery of Clionamide.64 
 
One of the first applications of sponge natural products in modern times was 
from an extract of Cryptotethia crypta in the 1950s. The sponge contained two 
nucleosides, spongothymidine (47) and spongouridine (48). 
  
 
 These were used as lead compounds to develop the drug Ara-A (49) an  antiviral 
compound.58  
(47) 
(46) 
(45) 
(48) 
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Contignasterol (50) is a steroid that was isolated from the sponge Petrosia 
contignata found in Papua New Guinea.65 When the structure of contignasterol 
was initially elucidated, the configuration of two of the chiral centres was 
ambiguous. All four of the possible configurations were synthesised and by 
comparing their 1H NMR spectroscopic data with that of natural contignasterols 
the absolute configuration was solved.  Contignasterol was found to have 
cytotoxicity when tested against rat mast cells and was therefore chosen as base 
structure from which to synthesise variants.65 
 
One of these variants IPL576-092 (51) showed good antiinflammatory and 
antiasthma activity. It was then advanced to Phase Two clinical trials.65, 66 
 
One of the drawbacks of natural products use from sponge species and marine 
species in general, is the relative difficulty of obtaining them compared to 
terrestrial species due to their environment. This means that sourcing large 
quantities of the compounds of interest can be difficult. In addition to this 
problem, some species only produce trace amounts of the natural product of 
interest. This can contribute to the relatively few marine compounds that have 
been advanced to clinical use.3 Even if species can be reliably sourced from the 
(49) (50) 
(51) 
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environment ecological impacts might prevent large scale collection. For 
example populations of the sponge Xestospongia muta form a major part of the 
habitat of reefs off the Florida Keys, so collection would have major ecological 
impacts.15 In sponges, bioactive molecules typically appear in concentrations too 
low to be commercially viable.67 However, there may be an efficient synthetic 
pathway to the same product or by cultivating sponges in aqua farms or within 
aquariums.67 Alternatively, if a symbiont such as a cyanobacterium (common 
candidates for symbiosis due to their nitrogen fixing ability) produces the 
secondary metabolite, it could potentially be isolated and cultivated 
separately.67, 68  
 
1.2.6 Cyanobacteria 
Cyanobacteria are a phylum of bacteria and are also called blue-green algae 
(because they contain chlorophyll).69 Similar to the sponge they are ancient and 
relatively simple compared with many other forms of life. 70 They are likely to 
have been the first oxygen producing photosynthetic organisms on earth and 
have developed a wide variety of secondary metabolites throughout their 
ecological history.71 On account of their adaptability, they have been able to 
inhabit almost every environment on earth and molecules already found in them 
have been shown to have antiviral, antibacterial, antifungal and anticancer 
activity. In addition to having a range of biological activity, cyanobacterial natural 
products comprise a variety of different structures including indoles, 
lipopeptides, polyketides, amides and alkaloids.72 The specific advantages of 
studying cyanobacteria to look for novel compounds is that different strains can 
have their own unique sets of secondary metabolites and once a strain is found 
with a desired molecule, cultivation of that strain may be relatively easy under 
the correct environmental conditions.73 
 
The specific genus of cyanobacteria Lyngbya has been found to produce many 
interesting natural products. In addition to this, they are easily accessible from 
the tropic and subtropical regions they inhabit and are able to be cultured in the 
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laboratory to produce workable quantities of the natural products of interest.70 
The natural product bisebromoamide (52)  was isolated from an unknown 
species of Lyngbya collected in Okinawa.74  
 
Bioassays were used to direct the fractionation process and HPLC was used to 
isolate the bioactive bisebromamide. After this, HRESIMS, 1H and 13C NMR 
spectroscopy were used to deduce the structure. To assign correct configurations 
to the eight chiral centres, the molecule was broken into chiral subunits and 
compared to enantiomeric standards by chiral HPLC. It was found that 
bisebromoamide contains a large proportion of D-amino acid chiral centres.74 
Where D-amino acids have been found in many other marine and terrestrial 
organisms, their presence has been essential to maximise the compounds 
bioactivity. These D-amino acids within organisms have shown biologically 
specific functions to regulate systems L-amino acids do not, such as parts of the 
nervous and endocrine systems.74 In marine organisms it has been speculated 
that they assist in maintaining osmoregularity in response to environmental 
changes.75, 76 When tested against HeLa cells bisebromoamide gave an IC50 value 
of 0.04µg/mL. It was also tested against 39 cancer cell lines and the average 
concentration required to inhibit growth by 50 % was 40 nmol/L.74 
 
 
 
(52) 
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From the both the species Lyngbya majuscula and Lyngbya polychroa 
dragonamide A (53) and six new acyclic peptides with analogous structures (54-
59) were isolated.70 
 
 
  
 
 
 
 
 
 
 
The seven compounds were tested for their antimalarial and antileishmanial 
activity. Only carbamin A (54), dragomabin (55) and dragonamide A (53) showed 
significant antimalarial activity, with IC50 values of 4.3, 6.0 and 7.7 µmol/L 
respectively. Dragonamides A (53) and E (59) showed antileishmanial properties 
A 
B 
C 
D 
E 
(53) R1=R2=R3= i-Pr, R4= PhCH2- Structure =A 
(54) R1= Bn, R2= R3= Me, R4= 4-MeO-PhCH2- Structure =B 
(55) R1= Bn, R2= R3= Me, R4= 4-MeO-PhCH2- Structure =A 
(56) R1= R2= R3= i-Pr, R4= i-Pr Structure =A 
(57) R1= R2= R3= i-Pr, R4= i-Pr Structure=C 
(58) R1= R2= R3= i-Pr, R4= i-Pr Structure =D 
(59) R1= R2= R3= i-Pr, R4= PhCH2- Structure =E 
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but the analogue dragonamide B (56) did not. This indicates that the aromatic 
group that is missing in B (56) but contained in  A (52) and E (59) is important for 
the bioactivity of the molecules.70 Malaria and Leishmaniasis infect millions of 
people in tropical regions each year and with the diseases gaining resistance to 
existing therapies finding compounds that can lead to new treatments is 
important for global health.77 
 
Apratoxins are another group of compounds isolated from a Lyngbya sp. 
(possibly Lyngbya bouillonii) with apratoxins A-C (60-63)  sourced from areas 
around Guam and Palau.78 
 
 
 
 
 
Apratoxin D (63) was  isolated from samples of Lyngbya majuscula and Lyngbya 
sordida found in Papua New Guinea.70 The apratoxins are a group of 
depsipeptides defined by a macrocycle containing a mixture of polyketide 
sections and amino acid residues.  The structure of apratoxin A was solved by 
analysis of the mass spectrum and several types of NMR data with the 
stereochemistry of the amino acid residues being determined by acid hydrolysis 
followed by chiral HPLC.79 Studies of the bioactivity of the apratoxins indicate 
that they inhibit cancer cells in many ways, including interfering with heat shock 
protein 90 and the secretory pathway.73 Apratoxin A has not been seen as a good 
candidate for further testing because of unsatisfactory in vivo test results.80 It has 
potent cytotoxicity but lacks the selectivity to make it a viable drug.79 It could still 
be useful as a lead compound for analogues developement as there is a current 
(60) R1= R2= R3= R4= Me 
(61) R1=H, R2= R3= R4= Me 
(62) R1= R3= R4= Me, R2= H 
(63) R1= R2= Me, R3= H, R4= (CH3)3CCH2- 
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synthetic pathway to apratoxin A and its mode of action is becoming better 
understood.80, 81  
 
 
Apratoxin E (64) was isolated from a sample of Lyngbya bouillni in Guam.82  
 
 
The structure of apratoxin E was solved by mass spectrometry, NMR 
spectroscopy and chiral HPLC. Apratoxin E was tested against a variety of cell 
lines along with  other compounds including apratoxin A and E-dehydroapratoxin 
A. Apratoxin A has more potency than both its dehydro analogue and apratoxin 
E. It has been concluded from this that the hydroxyl group on the polyketide unit 
is important for the cytotoxic effect.82 
  
(64) 
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Apratoxins A and E, as well as some of their analogues were analysed to identify 
their unique mode of action to inhibit cell growth through the secretory 
pathway. Cancer cells can be characterised by an overexpression in pro-growth 
signalling by the receptor tyrosine kinase (RTK).  Apratoxin A was found to stop 
the secretion of RTK activating ligands and RTK itself.81, 83 After the mechanism 
was understood, other less potent analogues were synthesised to try to find a 
more viable drug candidate with less toxicity problems that apratoxin A. Four 
analogues were developed; S1-3 (65-67), S4 (68) and the related compound 
apratoxin F (69) were also studied. 
 
 
 
 
The analogue S4 (68) was found to have even more potency than apratoxin A 
and was developed from combining elements of apratoxins A and E to try to get 
good tumour selectivity and strong anticancer properties.83 
 
A sample of the cyanobacterium Schizothrix sp. obtained by SCUBA divers off the 
coast of Panama was found to contain gallinamide A (70), a potent antimalarial 
compound.84 
 
 (70) 
(65) R1= R2= Me  R3= (S)-sec-Bu R4= PMB 
(66) R1=R2= -(CH2)3-  R3= Me R4= PMB 
(67) R1=R2= -(CH2)3-  R3= i-Pr R4= PMB 
(69) R1=R2= -(CH2)3- R3= (S)-sec-Bu  R4= Me 
 
(68) 
PMB= p-Mehtoxybenzyl ether 
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After initial fractionation, a pure sample of gallinamide A was isolated by HPLC. 
This was tested for its potency against Malaria and found to be moderately 
active with an IC50 value of 8.4 µmol/L.
84 Interestingly, the parent fraction was 
also tested against Malaria and showed an IC50 value of 1 µmol/L.
84 This could 
either suggest another molecule in the fraction with stronger bioactivity or 
possibly a synergistic effect of gallinamide A with another compound in the 
fraction.84 
 
In 1995 two isomers of curacin A (71), Curacins B (72) and C (73) were isolated 
from a sample of Lyngbya majuscula, a cyanobacterium obtained in Curacao.85 
 
 
 
The molecules are geometric isomers of curacin A (71) which had shown strong 
antimitotic activity.86 The Lyngbya majuscula sample was extracted and 
fractionated by chromatography. Curacins B (72) and C (73) were found to be 
related to A because of similar 1H and 13C NMR spectra and through further 
analysis were determined to be geometric isomers. Two different mixtures of the 
compounds were tested in a tubulin polymerisation assay using 95:5 and 1:1 C:B 
(71) 
 
(72) 
 
(73) 
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ratios. It was found that ratios of 95:5 and 1:1 gave IC50 values of 1.6 and 1.7 
µmol/L respectively only slightly higher than curacin A (71) (IC50 1.4 µmol/L). The 
study concluded that for the curacin molecules geometric, isomerism has little 
effect on the compounds antimitotic potency.85 
 
1.3 Bioassays and Cell Lines Used in Natural Product Research 
The above review mentioned bioassays and some of the information that they 
can give about the bioactivity of natural products. This section will detail specific 
cell lines used in bioassays and the use of the MTT assay to determine 
cytotoxicity of compounds  
 
1.3.1.1 HeLa Cells 
The HeLa cell line was the first human cancer cell line cultivated, as well as one of 
the most robust.87 The origin of the line is a sample of cervical carcinoma cells 
taken for a biopsy from the patient Henrietta Lacks (hence the name HeLa) who 
was receiving treatment at John Hopkins Hospital in 1951.88 The cells were 
placed in culture and found to grow rapidly. They can grow indefinitely in culture 
and their physiology is very well understood with over 65,000 scientific papers 
on HeLa cells published since their propagation.89 In practice the cells can grow 
indefinitely but like other cell lines, after many generations, mutations begin to 
build up and the cell biology can have significant differences from earlier 
passages. If the cell lines continue to be used at very high passages, this can have 
a detrimental effect on the reliability and reproducibility of results as higher 
passages can alter cells growth rates and response to stimuli.90 HeLa cells are 
useful to work with due to their adaptability to culture conditions, as well as a 
short doubling time (24 hours). The drawback of these characteristics is that the 
cell line can easily contaminate others and overgrow them, meaning careful 
technique and monitoring of cells lines is essential to avoid cross 
contamination.87 
 
29 
 
1.3.1.2 Using HeLa Cells to find bioactive compounds 
As a proliferative cancer cell line, the HeLa cell line has been commonly used for 
bioassays to indicate anticancer activity of compounds. By dosing the cells with 
known quantities of the compounds of interest (or a crude extract) and 
measuring cell activity (or cell death), potentially bioactive molecules can be 
identified and further assessed.91 If a crude extract is used, then bioassay can 
help decide whether fractionation is needed or not and if it is, which of the sub 
fractions contains the bioactive compound(s). The bioactivity of the pure 
fractions can be compared to the crude extract and an indication of which 
components are more or less potent can be obtained.92 This is what was done to 
find the compound benzobijuglone.93 Researchers used the MTT bioassay to 
guide the fractionation of an extract from the plant Juglans mandshurica and 
eventually found and characterised the quinone compound  
p-hydroxymethoxybenzobijuglone (74)  using spectroscopic methods.93  
 
 
A study looking at natural products contained in soybeans also used HeLa cells 
and the MTT assay to determine how well they induce apoptosis. 
 
 
The isoflavones genistein (75) and daidzein (76) have a synergistic effect, which 
was indicated by comparing the inhibitory effect of the crude soybean extract on 
HeLa cells to the pure genistein when concentration is accounted for.  The 
synergistic effect was further confirmed when it was found that the daidzen did 
not induce apoptosis but genistein with daidzen had more effect than genistein 
alone.16 
(75) (76) 
(74) 
30 
 
 
1.3.2 P388 Cells 
P388 are a murine leukaemia cell line commonly used to test for antitumour 
activity both in vivo and in vitro.94, 95 They are very chemosensitive and therefore 
very useful for detecting bioactive compounds from extracts.96 One study using 
both P388 and HL-20 (human leukaemia) cells, illustrates the useful information 
that can be gained from varied cell line testing. In the study, the compound 
pironetin (77) which previously tested positive for cytotoxic activity, was further 
examined with the aim of deducing the mechanism by which apoptosis was 
induced.97 
 
 
By the use of the two different cell lines, researchers were able to compare the 
biological effects of pironetin to get a better understanding of its mode of 
action.97, 98  
 
1.3.3 The MTT assay 
The 1,3,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) assay works 
on the basis that the mitochondrial dehydrogenases in healthy cells will reduce 
soluble yellow MTT to its insoluble purple formazan product.99 
(77) 
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Figure 1: (A) Metabolisation of MTT to Formazan and (B) absorbance spectra of MTT and 
MTT Formazan 
As shown in Figure 1, the absorbance ranges of the MTT and formazan differ 
sufficiently with their absorbance spectra and max absorbance peaks about 
100nm apart, that the MTT does not interfere with the spectroscopic 
measurement of the formazan.  Therefore the mitochondrial activity of the cells 
can be measured accurately by using the correct wavelength. The measured 
absorbances are proportional to incubation time and the concentration of MTT 
as well as to cell metabolism.100 
 
MTT has been used extensively for bioassays to test if samples are killing cells or 
inhibiting their mitochondrial activity and therefore measuring the samples 
cytotoxic potency. Despite its wide use, the factors that can lead to the reduction 
of MTT in cell culture are still not completely understood and many reducing 
agents in the cells, media or even in the added samples can be involved in 
reducing MTT to formazan.100 For example, the flavonoids luteteolin and 
quercetin have both been shown to reduce MTT in solution with no cells present. 
They were also shown to have greater reducing ability in RPMI-1640 with 10% 
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foetal bovine serum more than they did in ethanol.101 This illustrates why sample 
controls should be run as a part of all MTT assays. 
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2 Chemical Analysis of Coastal Marine Samples 
 
2.1 Introduction 
Marine organisms provide a rich source of natural products, due to their 
biodiversity and development of chemical defenses for survival. This results in a 
number of unique molecules that are of interest both for their chemical 
structures and their bioactivity. It is useful to know the structures of these 
molecules for synthesis or further study and any useful bioactivity they may have 
(anticancer or antibacterial properties etc.). 
 
A summer research project by undergraduate Biological Sciences student Nikki 
Webb, supervised by Professor Chris Battershill resulted in the collection and 
cataloguing of 58 marine samples from three sites around Mount Maunganui, 
New Zealand. Of the samples collected, eighteen were from Leisure Island (LI) 
(rocky shore habitat), twenty were from Rabbit Island (RI) (rocky reef habitat) 
and twenty from the Waikareao Estuary (WE). Photographs of each of the 
samples were taken and preliminary assignment of their taxonomy carried out. 
These samples were weighed, frozen and are currently stored at the Chemistry 
Department of the University Of Waikato. 
 
The taxonomic data given for these samples show that they comprise a diverse 
range of species. Of the 58 samples, fifteen are algae (eight Chlorophyta or green 
algae, four Rhodophyta or red algae and two Phaeophyta or brown algae with 
one unidentified to fit any of the groups). Twelve of the samples are sponges 
(Porifera), all from the class Demospongiae, three are sea snails and three are 
bivalve molluscs, five are Cnidarians consisting of four anemones and one coral. 
Other taxonomic groups represented include cyanobacteria and ascidians. A 
complete list of samples with their taxonomy is provided in Appendix One: Initial 
Survey of the Marine Samples. 
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The aim of this research was to screen these samples and determine if they 
contain any novel compounds with interesting structures or biological 
properties. The rationale of examining many different species is that high 
biological diversity will translate to high chemical diversity and hopefully the 
discovery of novel compounds. 
 
2.2 Initial Survey of the Marine Samples 
To analyse this collection of marine species, approximately two grams (wet 
weight) of subsample was taken from each and the biomass exhaustively 
extracted in methanol:dichloromethane. These crude extracts were stored as 
reference samples. A subsample of each was taken for analysis by LCMS, run on a 
reversed phase C18 column. Duplicates of each sample were run to confirm the 
reproducibility of the traces. For each sample, data was collected over a mass 
spectral range of 100-1500 Da and UV data with a wavelength range of 200-800 
nm. 
 
Analysis of the data identified halogenated compounds from their characteristic 
isotope patterns and the major peaks each chromatogram contained. On 
account of a soft ionisation technique being used (electrospray ionisation) most 
peaks were assumed to be pseudo-molecular ions (M+H+ or M+Na+) with very 
few if any fragment ions seen. A few common losses were identified in some 
mass spectra such as water (18 Da), carbonyl (28 Da) and ammonium (17 Da) 
losses. 
 
General analysis showed that in the majority of crude extract chromatograms 
(Appendix One: Initial Survey of the Marine Samples), metabolites eluted 
between 25 and 40 minutes. The common ions that appear in many of the traces 
were noted. This could indicate that primary metabolites common to many of 
the marine species are major components of these extracts. Even though these 
might not be of any chemical interest, as they are unlikely to be novel 
metabolites due to their commonality. Most of these compounds are likely 
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primary or common secondary metabolites which assisted the decision on 
whether to pursue the species for further analysis or not. 
 
2.2.1 Common High Mass Ions 
Many of the samples were found to have peaks that eluted at 35-37 minutes 
with masses between 730 and 750 Da. Six of these peaks commonly appeared as 
major peaks in the spectrum and were paired two mass units apart. They yielded 
ions with m/z of 731.5, 733.5, 740.5, 742.5, 745.5 and 747.5. Their peaks are very 
strong in the samples they appear in (Table 1). It is likely that these are either 
very long chain fatty acids or triglycerides, based on their relatively high 
molecular mass and their elution off the C18 column during the pure acetonitrile 
solvent phase of the LCMS run. This is also supported by the fact that lipids are 
common in marine species for energy storage.102 Whether these are fatty acids, 
triglycerides or another type of lipid, the two mass unit differences indicates the 
species are related with only a difference of one double bond group. The small 
differences that they have in retention time show that this is not an isotope 
effect but rather a minor functional group change.  
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Table 1: Common high mass ions observed in Algae Species Surveyed 
 
Algae are at the bottom of the food chain and tend to be the species that 
produce fatty acids.102 From the fifteen algal species surveyed eleven showed at 
least one the following six ions with m/z values 732.5, 734.5, 741.5, 743.5, 746.5 
and 748.5 with paired two mass unit differences eluting at 35-37 minutes. Table 
1 shows that the compounds with ions at m/z 746.5 and 748.5 have the same 
retention time, which could lead to the conclusion that it is an isotope pattern 
but closer analysis of the chromatogram showed that these ions only elute 
closely off the column and are probably related but not isotopes. The other algal 
species did not contain these peaks but did have ions that elute around that 
retention time with two mass unit differences that could potentially be lipids. 
 
Taxonomy (sample) Ions (m/z) and their retention times (min) 
 
731.5, 733.5 
(36.6, 36.9) 
740.5, 742.5 
(36.4, 36.7) 
745.5, 747.5  
(35.6) 
Ulva sp.(LI 2-5) ✓  ✓ 
 Codium sp.(LI 2-6) ✓   
Ulva  sp.(WE 1-1) ✓  ✓ 
Green Alga  sp.(WE 1-5) ✓   
Enteromorpha sp.(WE 2-16) ✓   
Entermorpha  sp (WE 2-17) ✓   
Green Alga  sp.(WE 2-19) ✓   
Brown Alga  sp.(LI 1-1)  ✓  
Sargassum  sp.(RI 2-20)   ✓ 
Plocamium  sp.(WE 1-2) ✓   
Gigartina  sp.(WE 1-4)  ✓  
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2.2.2 Analysis of the Mangrove Samples and More Common Ions 
Four of the samples analysed were different parts of a mangrove and one was 
lichen species that grew on the mangrove. These were the seeds (WE 1-9), leaves 
(WE 2-14), lichen (WE 2-15) and pneumatophores (WE 2-12). Unlike the other 
samples where a representative cross section of the species was taken for 
analysis this gives an insight into the localised chemistry of the species features. 
The chromatograms of the leaves, lichen and pneumatophores showed the same 
ions (740.5, 742.5) as those of the algae but the seeds did not (Table 2). This 
could mean that the compounds are produced later in the life cycle during the 
growth of the mangrove.  
Table 2: Compounds of interest in Mangrove samples 
Taxonomy (sample) Ions (m/z) and their retention times (min) 
 
740.5, 742.5 
(36.4, 36.7 min) 
Other prominent ions 
Mangrove Leaves (WE 2-14) ✓ 117 (8.1 min) 
Pneumatophores (WE 2-12) ✓  
Mangrove Lichen(We 2-15)  
757.5, 759.5 (36.3, 36.6 
min) 
Mangrove Seeds (WE 1-9)  117 (8.1 min) 
Root by-product (WE 2-13) ✓  
 
The 117 m/z ion is included, as it was seen in the chromatograms of thirteen of 
the marine samples, indicating that this is a primary or a very common secondary 
metabolite. It is found in such diverse groups such as algae, cnidarians, tunicates, 
molluscs (which make up five of the thirteen), in addition to the mangrove. This 
could also explain two other common ions found in a number of marine species, 
219 m/z (8.6 min) identified in twenty two of the species chromatograms and 
138 m/z (8.2 min) found in fourteen species.  
 
The last common ions identified in the chromatograms were potential sterols 
that had masses of 328 and 560 m/z with retention times of 27.2 and 27.9 
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minutes respectively. They are both quite small peaks and often appear in the 
same sample. Their retention times showed that they elute from the column just 
after the mobile phase becomes pure acetonitrile. The 328 m/z ion could be a 
fragment of cholesterol. The difference between them is 57.5 Da which is the 
same molecular mass as an isobutyl group part of the side chain of cholesterol. If 
this was a cholesterol fragment the number of large number of species it appears 
in would not be surprising due to the commonality of cholesterol. Neither of the 
ions are seen in the chromatograms of three of the twelve sponges where sterols 
are common which indicate they may not be sterols. Alternatively, the peaks 
could have been too small to be identified in those three chromatograms. 
 
2.3 Analysis of the Halogenated Compounds 
Halogenated molecules can be identified by the presence of characteristic 
isotope patterns and even if they are in low concentrations, peaks can often still 
be seen, as halogenated compounds ionise well. The most common halogens 
seen are chlorine and bromine whose isotopes appear two mass units apart in 
ratios 3:1 and 1:1 respectively. On the mass chromatogram, this is seen as two 
peaks with identical retention times differing by two mass units.  Depending on 
the peak ratios, the molecule can be determined to either contain chlorine or 
bromine. This can be extended to doubly halogenated molecules. In this case, 
three peaks will be seen in the ratio 9:6:1 for chlorine and 1:2:1 for bromine. 
 
From analysis of the chromatograms of the marine samples analysed in this 
research, six chlorinated and twelve brominated metabolites were detected. In 
addition, thirty two other ions identified appeared to be halogenated but the 
peak ratios were not distinctive enough to determine which halogens the 
molecules contain. Many of them seem to contain multiple halogen atoms and if 
they contained different halogens, would give an isotope ratio that may be 
difficult to identify. It is not surprising that more bromine than chlorine 
containing compounds were found. Despite the fact that the chlorine 
concentration in the marine environment is much greater than that of bromine it 
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more brominated compounds were found as bromine is more easily oxidised and 
therefore incorporated into a biosynthetic pathway.103, 104 
 
Based on the information gained in the chemical survey two of the marine 
species the cyanobacterium Lyngbya sp. (WE 2-20) and the sponge Cliona celata 
(RI 1-11) were selected for bulk extraction and further analysis. Three more 
samples selected for less detailed analysis were the tunicate Aplidium sp. (RI 2-
13), the cnidarian coral  Alcyonaria sp. (RI 2-14) and Ircinia sp. (RI 2-17) a sponge. 
These underwent micro-extractions, LCMS and tandem mass spectrometric 
analysis of some potentially novel compounds. 
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3 Analysis of Lyngbya sp. (WE 2-20) 
Lyngbya is a genus of cyanobacterium that has been a source of many new 
natural products due to high secondary metabolite production.105 From just one 
study of the species Lyngbya majuscula twelve new polyketide-polypeptide 
secondary metabolites were discovered. The compounds dolastatin 16 A (78), 
hantupeptin C (79), majusculamide A (80) and isomalyngamide (81) were found 
to have antifouling properties shown to reduce settlement of larvae.106  
 
 
  
(79) (80) 
(81) (82) 
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Another study of the species Lyngbya confervoides, resulted in the isolation of 
tiglicamides A-C (82-84), three new cyclodesipeptides. These compounds were 
tested against porcine pancreastic elastase and found to have IC50 values of 2.14-
7.28 µM.107 It has also been demonstrated with Lyngbya birgei that growth 
within the laboratory is possible under the correct conditions, which allows for 
more biomass to be obtained for extraction without external sourcing.108 
 
 
 
 
Lyngbya sp. was chosen on the basis that historically this genus has been an 
excellent source of novel metabolites. An LCMS analysis of the extract yielded a 
relatively simple chromatogram containing several peaks with half mass units 
including a major 656.6 m/z peak with several other minor peaks (710.5, 718.5, 
741.5 m/z). It was thought that this could be a novel peptide due to the half 
mass units of the peaks and no compounds found in the MarinLit database with a 
656.5 Da mass in the Lyngbya genus. There was also a large amount of biomass 
available for this species. The decision was based on the chemical and taxonomic 
data alone, as no bioassay data was available at the time. 
 
For further analysis, a bulk extraction of the sample was carried out with the 
resulting lyophilised powder being fractionated on a C18 reversed phase column. 
Twelve fractions were collected and analysed by LCMS. Three of the fractions 
(82) R = -CH2 CH2(C6H4)OH 
(83) R = -CH2(C6H4) 
(84) R = -CH2 CH2S(O)CH3 
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contained major amounts of the 656.5 m/z and also 741.5 m/z ions. One of these 
fractions contained approximately equal amounts of both compounds and was 
further fractionated by gel permeation chromatography on an LH-20 column to 
try to separate the two compounds. These fractions were then analysed by LCMS 
to determine the effectiveness of the separation. Despite their difference in 
mass, the two compounds were not well separated by the size exclusion column. 
It is unknown why but could possibly be due to structural features causing similar 
retention times. 
 
The fractions collected before and after those previously discussed were then 
fractionated separately by size exclusion chromatography, as they each 
contained one of the compounds of interest as major components along with 
minor metabolites. The fraction collected directly before had 656.5 m/z as a 
major component. This was then fractioned again to try to isolate the 656.6 m/z 
and analysis of the sub-fractions revealed that two of the fractions contained 
656.5 m/z as a major ion but still contained minor amounts of a 710.5 m/z.  The 
fraction collected after contained 741.5 m/z as the major ion and was 
fractionated again to further isolate the component that gave rise to this ion.  
Analysis of the sub-fractions showed that one of the fractions contained 741.5 
m/z as the major ion of interest. 
 
1H NMR spectra in CDCl3 were acquired for fractions containing 656.5 m/z and 
741.5 m/z to gain structural information. Both spectra looked similar, containing 
six major signals each with identical chemical shifts. The spectrum showed a 
small triplet at 0.8 ppm and a large singlet at 1.25 ppm. These are a methyl 
triplet and a large number of methylene groups in the same chemical 
environment. There is also a signal at 5.5 ppm indicating double bond(s) in the 
molecule and three signals at 1.6, 2.0 and 2.3 ppm that could be representative 
of methylene groups in three different chemical environments. Judging by the 
first two signals and information from the mass spectrum, these three signals 
could be explained by methylene adjacent to an ester group, another two bonds 
from an ester group and a methylene adjacent to a double bond. 
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The 656.5 m/z ion was subjected to tandem mass spectrometry (MS2 and MS3) 
for more structural information. The major fragments are given in Table 3. The 
table also shows subsequent fragmentations of 428.3 m/z and 236.1 m/z ions. 
Table 3: 656.5 m/z tandem mass spectrometry. 
Parent Ion (m/z) MS2  fragment (m/z) MS3  fragment (m/z) 
656.5 
446.3  
428.3 
144.1, 200.1, 341.5, 
384.4 
236.1 218, 131, 105.1 
 
The eighteen Da difference between the 236.1 m/z and 218 m/z ions indicates 
either water or an ammonia loss.  Also the 236 m/z ion appears to be cleaved 
into 131 and 105.1 m/z ions. So the compound probably contained a hydroxyl or 
amine group. The 428.3 m/z ions 44 Da loss to the 384.4 m/z ion could be an 
aldehyde group (CH2CHO). Also the 428.3 fragment has an 87 Da loss forming the 
341.5 m/z ion. One possibility is this is an alkyl chain terminating in an alcohol 
(CH2)4CH2OH). All of this analysis is speculative and would require other methods 
to corroborate the information.   
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4 Analysis of Cliona celata (RI 1-11) 
Cliona celata is a sponge species and similar to Lyngbya sp., the biology and 
history of natural products discovery in sponges is well documented. However 
there has been little chemical study on Cliona celata with only a few compounds 
reported on the MarinLit database. The biology of Cliona celata is regarded as 
very able to adapt to changing environmental conditions.109 The species is known 
to produce clionamide as a major metabolite, which was isolated in a derivatised 
form in 1978.64 In 2012 a crude extract was tested on smooth muscle cells and 
was found to inhibit enzyme activity as well as two other pathways.110  
N-acetylhomoagmatine has also been isolated from Cliona celata but was found 
to have only low toxicity when tested against corals.111 
 
Cliona celata was chosen for further analysis to examine a dibrominated 
(487.9/489.9/491.9 m/z) and monobrominated (408/410 m/z) pseudo-molecular 
ions seen in its chromatogram. In the LCMS trace and it which were not found in 
the MarinLit database. The sample was extracted in bulk and fractionated on a 
C18 reversed phase column. Fourteen fractions were collected and analysed by 
LCMS. The fractions RI 1-11.6 showed the strongest peaks of the samples of 
interest from the LCMS trace. Size exclusion chromatography was used to try to 
separate the dibrominated from the monobrominated compounds, however this 
was unsuccessful. This indicates that the compounds are related as they elute off 
the column at the same time. This is supported by their LCMS data as the 408, 
410 m/z ions can be explained by the loss of a bromine atom from the 
487.9/489.9/491.9 m/z ions. This also explains why the dibrominated ion is so 
much more intense as the soft ionisation used would not result in many bromine 
losses. 
 
NMR spectra was run on fractions RI 1-11.7 and RI 1-11.6 but the compounds of 
interest in the samples concentrations were to low give clear signals of what they 
were. There were also peaks produced by other compounds not separated 
during fractionation. Similarly a molecular formula was attempted to be 
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generated by isotope analysis from high resolution mass spectrometry. It was 
thought that the compound because of its halogenation would give a strong 
enough signal. However the brominated ions of interest were not abundant 
enough to produce a signal that a molecular formula could be derived from. 
 
Both the dibrominated and monobrominated ions were subjected to tandem 
mass spectrometry to obtain more structural information about the ions. The 
fragment ion are given in Table 4. For the MS3 fragmentation the strongest ions 
from the MS2 were targeted as well as the ones retaining bromines to confirm 
the presence of bromine from their losses. 
Table 4: Dibrominated and monobrominated tandem mass spectrometry. 
Parent Ion (m/z) MS2  fragment (m/z) MS3  fragment (m/z) 
488/490/492 
470/472/474(dibrominated), 
306/308 
 
428/430/432 (dibrominated) 349/351, 278/280, 227 
408/410 
393/395 306/308, 228, 172/174, 
350/352 195, 228, 271 
271  
 
The appearance of the 306/308 monobrominated ion indicated the loss of a 
bromine in addition to an unknown a 102 Da fragment. The 428/430/432 ion 
fragmented into 350/352 fragment gives differences of 81 Da and 79 Da 
indicating a bromine loss, supporting the observed isotope pattern. Analogous to 
this is the monobrominated 350/352 ion losing a Br79/Br81 to form the 271 
fragment ion. This also occurs from the 306/308 monobrominated ion 
fragmenting to the 228 Da. None of the data is sufficient to give any more 
definitive structural data but it does confirm the presence of the bromines in the 
compound. 
 
In addition to the brominated compounds, the sterols of Cliona celata were also 
investigated. Three of the fractions of Cliona celata were separated by reversed 
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phase chromatography and analysed by gas chromatography mass spectrometry 
(GCMS) with two of the fractions showing several sterols. Based on the data the 
samples were given probable matches from the NIST database. The three 
fractions analysed were RI 1-11.9, RI 1-11.10 and RI 1-11.14. From two of these 
fractions (RI 1-11.9, RI 1-11.10) data was obtained indicating both contained 
stigmasterol and sitosterol in minor amounts. The major sterol in both fractions 
was cholesterol at 41.47% in RI 1-11.9 and 34.81% in RI 1-11.10. In total eight 
sterols, were identified in RI 1-11.9 and thirteen in RI 1-11.10. 
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5 Analysis of Three Additional Extracts 
In addition to the bulk extractions three of the samples underwent another small 
scale extraction. The samples were Aplidium sp. (RI 2-13), Alcyonaria sp. (RI 2-14) 
and Ircinia sp. (RI 2-17). These extracts were then separated into five fractions 
each using a small scale reversed phase chromatography column and analysed by 
LCMS. The samples were chosen from ions seen in their chromatograms from the 
chemical survey and the crude extracts re-analysed by tandem mass 
spectrometry to generate fragements of these ions. 
 
Aplidium is a genus within the Tunicata subphylum. Generally the species from 
this subphylum lack the structural defenses like spicules and therefore likely rely 
on chemical defenses.15 Aplidium sp. (RI 2-13) had two ions analysed 452 m/z 
and 524 m/z by tandem mass spectrometry.  The results are given in Table 5. 
Table 5: RI 2-13 452 and 524 ions tandem mass spectrometry. 
Parent Ion (m/z) MS2  fragment(s) (m/z) MS3  fragments (m/z) 
452 
382, 354, 329, 128  
340 
281, 253, 217, 160, 146, 
142, 128 
524 
479, 399, 208, 278  
415 
345, 339, 299, 265, 228, 
231, 175, 356, 370, 329 
 
The fragments generated by 452 and the subsequent 340 m/z fractionation still 
give reasonably large ions making only speculative analysis possible. The 
fragment lost when 340 fragments to give 281 is 59 Da. This could be the loss of 
a CH2CH2CH2OH alcohol chain but this is only speculative. The lowest difference 
in the fragmentation of the 524 ion is 45 Da when it fragments to the 479 ion. 
There are several possibilities of what this could be including alcohol, carboxylic 
acid or amine groups (CH3CHOH, COOH, CH3CH2NH2).  
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Alcyonaria (Octocorallia) is a subclass from the phylum Cnidaria that occupy 
anywhere from the intertidal zone to the deep ocean. They can live either 
burrowed into hard substrates or dug into soft substrates.112 The sample of 
Alcyonaria sp. (RI 2-14) was found to contain a monobrominated compound 
(324/326 m/z). The tandem mass spectrometry of it is summarised in Table 6. On 
the initial chromatogram double and triple charged versions of this ion were 
seen. 
Table 6: RI 2-14 324/326 ions tandem mass spectrometry. 
Parent Ion (m/z) MS2  fragments (m/z) MS3  fragments (m/z) 
324-326 
264.9/266.9 142, 186, 222.9/224.9 
222.9/224.9  
 
The 264.9 m/z to 186 m/z ion gives a 79 Da loss showing the bromine is being 
lost. The 44 Da difference between the 142 and 182 m/z ions could mean that 
CO2 as well as a bromine atom is lost. If this is the case, the compound may 
contain a carboxylic acid group. From the rest of the data, nothing else can be 
determined due to the low number of fragments and their difference giving too 
many potential sub-structures. 
 
The sponge (Porifera) from the genus Ircinia (RI 2-17) was analysed and one 
compound was identified as potentially interesting. Sponges produce many 
potentially interesting metabolites either directly or from the symbiotic 
microorganisms that tend to inhabit them and make up as much as 35% of their 
biomass.113 The identified compound yielding the 606 m/z ion, had no matches 
found on MarinLit within its genus. The table below summarises the tandem 
mass spectrometry data. 
Table 7: RI 2-17 606 m/z ion tandem mass spectrometry. 
Parent Ion (m/z) MS2  fragments (m/z) MS3  fragments (m/z) 
606 
208, 249, 415, 546, 589  
502 
440, 485, 381, 216, 191, 
149, 468 
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From 606 m/z to 589 the loss of a 17 Da OH or NH3 group can be seen. This is 
repeated in the 502 m/z to 485 m/z ion difference. Another 17 Da difference 
between the 485 and 468 fragments indicating there could be another OH or NH3 
group lost. Like the other two samples, there are more potential structures for 
fragments but with no corroborative evidence and the large number of 
combinations that can arise with this data, they are speculative. 
 
While this analysis has not revealed much substantial information about the 
compounds that these three species contain, it does provide some information if 
further research on these samples was to be pursued.  
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6 Bioassay Screening and Method Development 
A common way to determine if a crude extract contains any bioactive natural 
products is to screen it through a bioassay. Initially, a pre-screening of all 58 
marine samples utilising HeLa and P388 cell lines was to be undertaken to 
determine which samples would be good candidates for further study. However, 
because of the time taken for method development and to screen all the 
samples, the chemical analysis continued with the bioassay results to be added 
later. 
 
The purpose of the in vitro MTT assay used in this research was to assess the 
cytotoxicity of the crude extracts to generate IC50 values. The assay is based on 
mitochondria of cells reducing yellow MTT to its purple formazan product and 
the spectroscopic absorbance is then measured (see Figure 1: (A) Metabolisation 
of MTT to Formazan and (B) absorbance spectra. (Section 1.3.3 page 31)) .99 If 
cell growth is inhibited or apoptosis induced by cytotoxic agents less MTT will be 
reduced and the measured absorbances will be lowered. The cells lines used for 
biological screening were the immortal human cancer-derived HeLa cells and 
murine P388 D1 lymphocytic leukaemia cells.  Different cell lines were used 
because they may have different responses to bioactive metabolites. HeLa cells 
are largely used to test for anti-cancer properties. P388 cells have been used for 
testing antitumour potency.96 
 
The initial method used for the MTT assay was based on protocols from the 
University of Canterbury.114 Following this protocol, several experiments gave 
inconclusive results of cell growth, including no inhibition seen from the known 
cytotoxin pterocellin A with a reported IC50 value of 477 ng/mL against the P388 
cell line.115 The method of the assay was examined to determine the reasons for 
this and a review of the literature found that acidified isopropanol which was 
being used as a solubiliser, did not effectively dissolve formazan crystals, even 
with agitation.  It also stated that DMSO dissolved formazan crystals rapidly.23  
51 
 
 
An experiment was conducted to compare solubilising agents. HeLa cells were 
seeded on a 96 well plate at the same seeding density and for the same length of 
time as indicated in the provided protocol.114  MTT was added and after four 
hours of incubation two different solubilisers were each added to half the wells. 
These were acidified isopropanol 0.1M and acidified isopropanol 0.1M with 10% 
triton X.   
 
(A) 
 
(B) 
 
(C) 
Figure 2: (A) Media  (B) acidified isopropanol added  (C) acidified isopropanol+10% 
triton X 
Figure 2 shows the results of the experiments with acidified isopropanol (Figures 
2B+2C) leaving much of the formazan (black spots) undissolved and the acidified 
isopropanol with triton X more effective at dissolving the crystals. Because 
neither solubiliser completely dissolved the formazan, a small amount of DMSO 
was added to some of the wells for comparison. The media control well was also 
photographed (Figure 2A) showing no reduction of the yellow MTT as expected. 
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 (A)  (B) 
 (C)  (D) 
Figure 3: (A) Acidified isopropanol+DMSO, (B) acidified isopropanol+1hr incubation,  
(C) acidified isopropanol+triton X+DMSO and (D) acidified isopropanol+triton X+1 hr 
incubation. 
Figure 3Figure 1 shows the effectiveness of DMSO in dissolving the formazan 
when added to the acidified isopropanol (Figure 3A) and the complete 
solubilisation of formazan when DMSO is added to acidified isopropanol with 
triton X (Figure 3C). By incubating the plate at 37°C for one hour, the 
isopropanol+triton X (Figure 3 (D)) also completely dissolves the formazan. The 
observed results agree with the measured absorbance values in Table 8. Values 
are calculated from a 570 nm test measurement minus a 655 nm reference 
measurement. 
Table 8: Absorbance values for different solubilisation conditions (5000 HeLa 
cells/well) 
Solubiliser Additional Conditions 
 None   DMSO 20µL 1hr incubation 
Acidified isopropanol 0.380 0.582 0.478 
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Acidified isopropanol+triton X 0.620 1.22 1.14 
Based on these results, the solubiliser used in the protocol was modified to 100 
µL of acidified isopropanol (0.1M)+10% triton X with 20µL of DMSO added to 
each well and a one hour incubation time, to ensure that all of the formazan was 
dissolved. 
 
In addition to testing the solubiliser, the HeLa cells were tested for growth 
response over six days against sodium azide (Figure 4). 
 
Figure 4: Sodium azide treatments of cells 
It was found that the HeLa cells were being inhibited by the sodium azide and 
were therefore a response from the cells could be obtained with addition of a 
cytotoxin. The P388 cells showed inhibition measuring 61% of the cell control 
when grown in wells with 50 mM of sodium azide. For subsequent testing 
sodium azide was used a positive control for both P388 and HeLa cells with 50 
mM concentrations being added to some wells. 
  
Using the altered method, the samples were tested against the HeLa and P388 
cell lines. However, there was still inconsistent data observed. Many of the 
samples showed activity either much lower or much higher than the cell control. 
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For the lower activity, this could be explained by an effect of the extract except 
all the concentrations produced approximately the same response rather than a 
dose response curve that would be expected from a cytotoxin. The crude extract 
from the brown alga Xiphophora (LI 2-3) did exhibit an expected trend for both 
the P388 and HeLa cell lines. 
 
Figure 5: P388 LI 2-3 MTT Response curve 
 
Figure 6: HeLa LI 2-3 MTT Response curve 
Using the trend lines from the graph, IC50 values of 17079 ng/mL for P388 and 
14547 ng/mL for HeLa were calculated. Two of the P388 data points gave 
responses about 7% higher than the cell control. This could be random error 
masking any effect at the low concentrations. Because of the inconsistencies 
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with the cell controls and the small amount of data used to calculate each point 
this does not confirm if the sample actually contains a cytotoxin. From the 
bioassay survey it shows the clearest dose response effect on the cells. More 
reliable results and replication of the experiment is needed to confirm if there is 
a reproducible effect.
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7 Experimental Methods 
7.1 General Experimental Methods 
All of the marine samples were stored at -20°C and removed only to take a 
subsample for extraction.  
 
Crude extraction was carried out using drum grade distilled 
methanol:dichloromethane (3:1) for the solvent and a Janke and Kunkel IKA 
Labortechnik Ultra Turrex T25 blender stick for homogenising the samples. 
Solvent was removed using a rotary evaporator (BÜCHI Rotovapor R110 with 
BÜCHI Vacuum Pump V-700) with samples warmed in a water bath (BÜCHI 461) 
at 40°C. Lyophilisation was carried out in a Labconco freeze dry system. 
 
The LCMS data was generated on a Dionex Ultimate 3000 HPLC system with a C18 
column connected to a Bruker amaZon X electrospray ionisation mass 
spectrometer in positive ion mode. All LCMS analysis was carried out using the 
same method with a two solvent gradient profile (Figure 7).The solvents used 
were water (type 1) with 0.05% trifluroacetic acid (solvent A) and acetonitrile 
(solvent B). 
 
Figure 7: LCMS C18 reversed phase chromatography solvent gradient profile 
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Methanol (250µL) was added to each crude extract vial and the solution was 
pipetted through a syringe with a 0.2 µm filter into a LCMS vial followed by two 
500µL HPLC grade methanol washes. The syringe plunger was used to provide 
pressure to force the sample and wash methanol through the filter. 
 
Both the C18 and LH-20 column fractions were dried down under vacuum by 
rotary evaporation while being samples heated in a water bath at 40°C to 
remove the majority of the solvent. All fractions were then transferred into 
weighed scintillation vials and the remaining solvent completely in a heating 
block (Lab-Line Multi-block) at 36°C under nitrogen gas before being re-weighed 
and the weights calculated.  
 
GCMS analysis was carried out on a Hewlett Packard 6890 Gas Chromatogram 
System connected to a Hewlett Packard 5973 Mass Selective Detector. 
Underivatised samples were dissolved in distilled dichloromethane and inserted 
into the machine by direct injection (RI 1-11.9 1µL, RI 1-11.10 5µL). The initial 
temperature was 80°C and increased at 30°C per minute until it reached 310°C. 
The temperature increase then changed to 6°C per minute for 5 minutes when 
the temperature was held at 340°C until the end of the run. The total run times 
were: RI 1-11.9 18.17 min and RI 1-11.10 33.33 min. 
 
 The small scale columns were Pasteur pipettes plugged with cotton wool were 
packed with C18 YMC gel 120Å (500mg). The column was packed dry and 
methanol then water:methanol 1:1(2mL) and water (2mL) run through the 
column to equilibrate it. Pressure was applied using a rubber pipette sucker to 
force the liquids through the column. 
 
Both HeLa and P388 cells used in this research were grown in a humidified 
Heraeus Cell 240 incubator at 37°C and 5% CO2. Cell media was changed every 3 
days and cells were split once per week. A stock of new cells was grown once the 
current cells passage number approached 30. All experimental work used cells 
passaged less than 35 times. Handling of cells was carried out in a Hera Safe 
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laminar flow hood. All cells were counted using a Nikon Eclipse TS100 
Microscope and photos taken on a Coolpix 4500 Nikon camera. The HeLa cells 
were acquired from the Biology Department of the University of Waikato and the 
P388 cells provided by AgResearch. 
 
7.1.1 Solution Preparations 
7.1.1.1 Phosphate buffered saline (PBS) 
8g NaCl (137 nM) 
0.2 KCl (2.7 nM) 
1.44 g Na2HPO4 (4.0 mM) 
0.24 g KH2PO4 
1L of sterile H2O 
7.1.1.2 Acidified Isopropanol 
20 mL isopropanol 
1.6 mL 1M HCl 
7.1.1.3 MTT in PBS 
38 mg MTT 
10 mL PBS 
7.1.1.4 Sodium Azide Solution 100mM 
0.065 g NaN3 
10 mL sterile H2O 
Diluted to 1 mM for treatments. 
 
7.2 Chemical Methods 
7.2.1 Crude Extraction of Marine Samples 
Each sample (~2g) was weighed out and methanol: dichloromethane 3:1 (30mL) 
added. The sample was then blended and vacuum filtered. This process was 
repeated for exhaustive extraction of the biomass. Distilled water (100 mL) was 
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added to the resulting filtrate and the solution was frozen by dropwise addition 
to liquid nitrogen. The samples were then freeze-dried for 48 hours to remove 
the solvent. The crude extract was transferred into pre-weighed vials and the 
weight calculated. The extracts are stored in the Chemistry Department of the 
University of Waikato as reference extracts. 
 
7.2.2 Bulk Extraction Method 
Bulk extractions were carried out on Lyngbya sp. (WE 2-20 )and Cliona celata (RI 
1-11). Two hundred grams of sample was weighed out and blended with 75mL of 
solvent (methanol: dichloromethane ratio 3:1). This was then vacuum filtered 
and the filtrate collected. The residue was recovered then 50mL of solvent 
(methanol: dichloromethane ratio 3:1) added and the sample was blended, 
filtered and collected. This process was repeated five times to exhaustively 
extract the biomass with the residue being recovered each time. The solvent was 
then removed using a rotary evaporator, followed by lyophilisation to yield a 
crude extract. 
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7.2.3 Reversed Phase Chromatography of Cliona celata (RI 1-11) and 
Lyngbya sp. (WE 2-20) 
Solid samples were loaded onto a reversed phased C18 YMC gel (120Å, 150g) 
packed glass column and eluted using the solvent gradient outlined (Tables 9/10) 
with applied nitrogen gas pressure (20 psi). 
Table 9: Reversed phase chromatography solvent gradient of RI 1-11 
Solvent Volume (mL) 
H2O 100 
H2O:MeOH(7:3) 100 
H2O:MeOH(1:1) 100 
H2O:MeOH(3:7) 100 
H2O:MeOH(1:9) 100 
MeOH 100 
MeOH 100 
MeOH:CH2Cl2(9:1) 100 
MeOH:CH2Cl2(1:1) 100 
CH2Cl2 100 
CH2Cl2 100 
MeOH 100 
MeOH: H2O(1:1) 100 
H2O 150 
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Table 10: Reversed phase chromatography solvent gradient of WE 2-20 
Solvent Volume(mL) 
H2O 100 
H2O:MeOH(1:1) 100 
H2O:MeOH(3:7) 100 
H2O:MeOH(1:9) 100 
MeOH 100 
MeOH 100 
MeOH:CH2Cl2(9:1) 100 
MeOH:CH2Cl2(1:1) 100 
CH2Cl2 100 
MeOH 100 
MeOH: H2O(1:1) 100 
H2O 150 
 
7.2.4 Small Scale Reversed Phase Chromatography 
Samples were loaded onto the column as solids and eluted using a five step 
solvent gradient with 5mL fractions from each solvent collected and the column 
run dry between fractions. The solvent gradient was; H2O, H2O:MeOH (1:1), 
MeOH, MeOH:CH2Cl2 (1:1), CH2Cl2. Pressure was using a rubber dropper bulb 
applied to force all the solvent through the column. 
7.2.5 Size Exclusion Chromatography 
Fractions of Cliona celata and Lyngbya sp. extracts were dissolved in minimal 
methanol and loaded onto a Sephadex LH-20 (150g) packed glass column. The 
samples were eluted off the column using methanol and sub-fractions were 
collected at regular intervals.  
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7.3 Cell Culturing and Bioassay Methods 
 
7.3.1 Splitting of HeLa Cells 
The media was removed and trypsin/EDTA (2 mL) was added. The cells were 
incubated for 10 minutes. The flask was removed from the incubator and tapped 
to dislodge the cells. After the cells were dislodged media (Gibco Life 
Technologies) was added (8mL). The cell solution was transferred into a Falcon 
tube and centrifuged for five minutes (400 rpm). The supernatant liquid was 
poured off and the cell pellet re-suspended in additional media (4 mL). An 
aliquot of this solution(1 mL) was pipetted into a new culture flask (60 mL 
Nunclon) containing fresh media (9 mL). The flask was then labelled with the 
date and the passage number then re-incubated. 
 
7.3.2 Splitting of P388 Cells 
The adherent cells were scraped from the bottom of the flask. The cell solution 
was transferred to a Falcon tube and centrifuged at 400 rpm for five minutes. 
The media was poured off and the remaining pellet of cells was re-suspended in 
fresh media (4 mL).  One quarter of the suspension was seeded to a new culture 
flask (60mL Nunclon) containing fresh media (9mL), the date and passage 
number were recorded on the flask and the cells re-incubated. 
  
7.3.3 Preparation of the Cell Media 
In a laminar flow hood (Heraeus) sodium bicarbonate (15 g/L, 2.5 mL), of 10mM 
nonessential amino acids (1 mL) and penicillin-streptomycin (2mL) was pipetted 
into an autoclaved 100 mL measuring cylinder. Dulbeccos Modified Eagle 
Medium (Gibco Life Technologies) was added until the total volume was solution 
up to 100 mL, 10 mL was discarded and fetal bovine serum (10 mL) added. The 
solution was then filtered using a sterile 60 mL syringe with a 0.2 µm filter. 
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7.3.4 MTT Assay Methods 
7.3.4.1 Counting the Cells 
The cells were split and an aliquot from the suspension (50 µL) added to 0.4% 
trypan blue dye in phosphate buffered saline (50 µL). Half of this solution was 
transferred onto a hemocytometer, the cells were counted and the cells per 
millilitre in the suspension calculated. An aliquot determined by the cells/mL of 
the suspension was then transferred to a Falcon tube and cell media added, to 
give a cell solution with the appropriate seeding density. Seeding density for 
HeLa cells was 5000 cells/well and for P388 cells 11,300 cells/well. 
 
7.3.4.2 Preparing the sample dilutions 
Serial dilutions of the samples were prepared on a 96 well plate (Greiner Bio-one 
CellStar) (Figure 8). Media (280 µL) was added to well 5A (see Figure 8) then 
150µL of media was added to each of the 6-12A wells. An aliquot (40 µL) of the 
test samples (1 mg/mL of crude extract in methanol) was added to the 5A (1/8 
dilution). Then 150 µL of the resulting solution was transferred to 6A and 
triturated. This process continued down the whole row to give a series of half 
dilutions. Figure 8 gives the resulting serial dilution concentrations in row A (5-
12) in ng/mL. The process was repeated to prepare additional samples to be 
tested. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A     125000 62500 31250 15620 7810 3900 1950 975 
Figure 8: Serial dilution concentration layout of one row of a 96 well plate. 
7.3.4.3 Preparing the test plate 
The cell solution (135 µL) was pipetted into all of the wells of columns 3-12 of in 
a 96 well test plate with columns 1-4 used as control wells. The media control 
(column 1) consisted of the cell media (150 µL) added to each well in the column. 
The sample control (column 2) had an aliquot of media (135 µL) and an aliquot 
(15 µL) crude extract in methanol (concentration 1mg/mL). Media (15 µL) was 
added to column three (cell control). For the solvent control, a 1:80 dilution of 
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methanol in cell media (15 µL) was added to each well in column four. The 
methanol 1:80 dilution was used as for the solvent control to give the same 
methanol concentration as column 5, which has the highest concentration of 
methanol from the test samples. 
 Control Wells Sample Test Dilutions 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Media Sample Cell Solvent         
B             
C             
D             
E             
F             
G             
H             
Figure 9: Diagram of a 96 well plate 
7.3.4.4 Adding the samples into the test plate 
Columns 5-12 had an aliquot (15 µL) of the sample dilution from the test plate 
added (1/10 dilution from the concentrations in Figure 8). The position of the 
serial dilutions on the sample plate corresponded to the position they were 
added to the test plate. So for the 12A well from the sample dilution plate, 15 µL 
of solution was transferred to the 12A well on the test plate. The samples were 
run in duplicate so the same sample dilutions were used for every two rows of 
the test plate. Therefore an aliquot of 12A (sample plate) was also added to the 
well 12B on the test plate.  
7.3.4.5 Measuring the Formazan Product 
The cells were incubated for three days at 37°C, then MTT (3.8 mg/mL, 20 µL) 
was added to each well and the cells incubated for four hours. After incubation, a 
solution of acidified isopropanol (0.1N HCl) with 10% triton X (100 µL) and DMSO 
(20 µL) was added to each well on the test plate. The plate was then incubated 
for one hour after which it was shaken on an IKA MS 1 Minishaker for 5 minutes 
 65 
 
to assist in solubilising the formazan. The absorbances were measured at 655 nm 
(reference) and 570 nm (test) on a Bio-Rad 680 Microplate Reader. The reference 
numbers were subtracted from the test numbers to give the corrected values. 
 
7.3.5 Sodium Azide (NaN3) Cell Treatments 
Cells were seeded at 50,000 cells/mL in each well of three 24 well plates. Sodium 
azide solution (1 mM) was added to each well of two plates at 50 µL and 100 µL 
respectively. Every 24 hours each plate had the media removed from three of its 
wells and 200 µL of trypsin/EDTA added. After ten minutes of incubation 800 µL 
of cell media was added to each of the three wells. For each well, an aliquot of 
the suspension (50 µL) was added to 0.4% trypan blue dye in phosphate buffered 
saline (50 µL) and counted on a hemocytometer.  
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8 Appendices 
 
8.1 Appendix One: Initial Survey of the Marine Samples 
 
Table A1.1: Leisure Island Sample Taxonomy 
Leisure Island Samples (subsite-
sample number) 
Genus Species/Description 
LI 1-1 Brown Alga 
LI 1-2 Green  Anemone 
LI 2-3 Xiphophora sp. 
LI 2-4 Spiach sp. (Sausage Alga) 
LI 2-5 Ulva sp. (Sea lettuce) 
LI 2-6 Codium sp. 
LI 2-7 Filamentous Cyanobacterium 
LI 2-8 Pterocladia sp. 
LI 2-9 Glossophoria sp. 
LI 2-10 Panncea sp. 
LI 2-11 Tethya sp. 
LI 2-12 Haplosclerida  (Order) 
LI 3-13 Isactinia sp. 
LI 3-14 Actinia sp. 
LI 3-15 Actinia sp. 
LI 3-16 Patiriella regularis 
LI 3-17 Cliona celota  
LI 4-18 Xenostrobus pulex 
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Table A1.2: Rabbit Island Sample Taxonomy 
Rabbit Island Samples (subsite-
sample number) 
Genus Species/Description 
RI 1-1 Callyspongia regularis 
RI 1-2 Cnemidocarpa + Aplidium 
RI 1-3 Chondropsis sp. 
RI 1-4 Aplidium scabellum 
RI 1-5 Cnemidocarpa bicornuta 
RI 1-6 Ancorina alata 
RI 1-7 Tethya aurautium 
RI 1-8 Polymastia croceus 
RI 1-9 Lophon minia 
RI 1-10 Biemna sp. 
RI 1-11 Cliona celata 
RI 2-12 Scutus breviculus 
RI 2-13 Aplidium (sea squirt) 
RI 2-14 Alcyonaria sp. 
RI 2-15 Tethya ingalli 
RI 2-16 Aptos sp. 
RI 2-17 Ircinia sp. (horny sponge) 
RI 2-18 Chrondria sp. (red alga) 
RI 2-19 Terraclaydia sp. 
RI 2-20 Sargassum sp. 
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Table A1.311: Waikareao Estuary Sample Taxonomy 
Waikareao Estuary Samples (subsite-
sample number) 
Genus Species/Description 
WE 1-1 Ulva sp. (sea lettuce) 
WE 1-2 Plocamium 
WE 1-3 Bryozoan 
WE 1-4 Gigartina 
WE 1-5 Spiky green alga 
WE 1-6 Sea grass 
WE 1-7 Macomona liliana 
WE 1-8 Austrovenus stutchburyi 
WE 1-9 Mangrove seeds 
WE 2-10 Amphibola sp. 
WE 2-11 Zeacumantus (screw shell) 
WE 2-12 Pneumatophores (aerial roots) 
WE 2-13 Aerial root by-product 
WE 2-14 Mangrove leaves 
WE 2-15 Mangrove lichen 
WE 2-16 Enteromorpha sp. 
WE 2-17 Enteromorpha/Ulva sp. 
WE 2-18 Bacterial flock 
WE 2-19 Green alga 
WE 2-20 Lyngbya sp. 
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Figure 10: LCMS Chromatogram of crude extract LI 1-1 
 
 
Figure 11: LCMS Chromatogram of crude extract LI 1-2 
 
 
Figure 12: LCMS Chromatogram of crude extract LI 2-3 
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Figure 13: LCMS Chromatogram of crude extract LI 2-4 
 
 
Figure 14: LCMS Chromatogram of crude extract LI 2-5 
 
 
Figure 15: LCMS Chromatogram of crude extract LI 2-6 
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Figure 16: LCMS Chromatogram of crude extract LI 2-7 
 
 
Figure 17: LCMS Chromatogram of crude extract LI 2-8 
 
 
Figure 18: LCMS Chromatogram of crude extract LI 2-9 
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Figure 19: LCMS Chromatogram of crude extract LI 2-10 
 
 
Figure 20: LCMS Chromatogram of crude extract LI 2-11 
 
 
Figure 21: LCMS Chromatogram of crude extract LI 2-12 
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Figure 22: LCMS Chromatogram of crude extract LI 3-13 
 
 
Figure 23: LCMS Chromatogram of crude extract LI 3-14 
 
 
Figure 24: LCMS Chromatogram of crude extract LI 3-15 
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Figure 25: LCMS Chromatogram of crude extract LI 3-16 
 
Figure 26: LCMS Chromatogram of crude extract LI 3-17 
 
Figure 27: LCMS Chromatogram of crude extract LI 4-18 
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Figure 28: LCMS Chromatogram of crude extract RI 1-1 
 
Figure 29: LCMS Chromatogram of crude extract RI 1-2 
 
 
Figure 30: LCMS Chromatogram of crude extract RI 1-3 
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Figure 31: LCMS Chromatogram of crude extract RI 1-4 
 
 
Figure 32: LCMS Chromatogram of crude extract RI 1-5 
 
 
Figure 33: LCMS Chromatogram of crude extract RI 1-6 
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Figure 34: LCMS Chromatogram of crude extract RI 1-7 
 
 
Figure 35: LCMS Chromatogram of crude extract RI 1-8 
 
 
Figure 36: LCMS Chromatogram of crude extract RI 1-9 
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Figure 37: LCMS Chromatogram of crude extract RI 1-10 
 
 
Figure 38: LCMS Chromatogram of crude extract RI 1-11 
 
 
Figure 39: LCMS Chromatogram of crude extract RI 2-12 
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Figure 40: LCMS Chromatogram of crude extract RI 2-13 
 
 
Figure 41: LCMS Chromatogram of crude extract RI 2-14 
 
 
Figure 42: LCMS Chromatogram of crude extract RI 2-15 
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Figure 43: LCMS Chromatogram of crude extract RI 2-16 
 
 
Figure 44: LCMS Chromatogram of crude extract RI 2-17 
 
 
Figure 45: LCMS Chromatogram of crude extract RI 2-18 
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Figure 46: LCMS Chromatogram of crude extract RI 2-19 
 
 
Figure 47: LCMS Chromatogram of crude extract RI 2-20  
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Figure 48: LCMS Chromatogram of crude extract WE 1-1 
 
 
Figure 49: LCMS Chromatogram of crude extract WE 1-2 
 
 
Figure 50: LCMS Chromatogram of crude extract WE 1-3 
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Figure 51: LCMS Chromatogram of crude extract WE 1-4 
 
 
Figure 52: LCMS Chromatogram of crude extract WE 1-5 
 
 
Figure 53: LCMS Chromatogram of crude extract WE 1-6 
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Figure 54: LCMS Chromatogram of crude extract WE 1-7 
 
 
Figure 55: LCMS Chromatogram of crude extract WE 1-8 
 
 
Figure 56: LCMS Chromatogram of crude extract WE 1-9 
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Figure 57: LCMS Chromatogram of crude extract WE 2-10 
 
 
Figure 58: LCMS Chromatogram of crude extract WE 2-11 
 
 
Figure 59: LCMS Chromatogram of crude extract WE 2-12 
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Figure 60: LCMS Chromatogram of crude extract WE 2-13 
 
 
Figure 61: LCMS Chromatogram of crude extract WE 2-14 
 
 
Figure 62: LCMS Chromatogram of crude extract WE 2-15 
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Figure 63: LCMS Chromatogram of crude extract WE 2-16 
 
 
Figure 64: LCMS Chromatogram of crude extract WE 2-17 
 
 
Figure 65: LCMS Chromatogram of crude extract WE 2-18 
0 5 10 15 20 25 30 35 40 45 Time [min]
0.0
0.5
1.0
1.5
2.0
10x10
Intens.
WE 2-16_RC7_01_7160.d: BPC 100.0-1500.0 +All MS
0 5 10 15 20 25 30 35 40 45 Time [min]
0.0
0.5
1.0
1.5
2.0
10x10
Intens.
WE 2-17_GE1_01_7003.d: BPC 100.0-1500.0 +All MS
0 5 10 15 20 25 30 35 40 45 Time [min]
0
1
2
3
4
9x10
Intens.
WE 2-18_GA2_01_7384.d: BPC 100.0-1500.0 +All MS
 88 
 
 
Figure 66: LCMS Chromatogram of crude extract WE 2-19 
 
 
Figure 67: LCMS Chromatogram of crude extract WE 2-20 
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8.2 Appendix Two: Separation Trees and Diagrams of Marine Species 
Analysed in Chapters 3-5
  
9
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Cliona celata, RI 1-11 wet weight 200 g
Methanol:dichloromethane (3:1) 
RI 1-11.1 
<0.1mg 
 
 
11.2 
<0.1mg 
 
 
 
 
11.3 
321.4mg 
 
 
 
11.4 
107.1mg 
11.5 
58mg 
11.6 
161.3 mg 
11.7 
142.9 mg 
11.8 
115 mg 
11.9 
194.4 mg 
11.10 
156.1 mg 
11.11 
2 mg 
11.12 
7.1 mg 
11.14 
107 mg 
RI 1-11 Extract 6.8736 
g 
C18 Column (75g) 
11.6.1 
10.2 mg 
11.6.2 
3.8 mg 
11.6.3 
2.9 mg 
11.6.4 
8.9 mg 
11.6.5 
3.9 mg 
 
 
11.6.6 
7.7 mg 
 
 
11.6.7 
7.0 mg 
 
11.6.8 
2.7 mg 
 
11.6.9 
2.5 mg 
11.6.10 
<0.1mg 
 
11.6.11 
<0.1mg 
 
11.6.12 
<0.1mg 
 
11.6.13 
<0.1mg 
 
11.6.14 
<0.1mg 
 
LH-20 Column (150g) 
LH-20 Column (150g) 
 
11.7.1 
1.9mg 
11.7.2 
2.1mg 
11.7.3 
6.2mg 
 
11.7.4 
25.9mg 
11.7.5 
85.4mg 
11.7.6 
8.2mg 
11.7.7 
16.3mg 
11.7.8 
10.9mg 
11.7.9 
5.5mg 
11.7.10 
7.8mg 
11.7.11 
5.6mg 
11.7.12 
5.2mg 
11.7.13 
4.5mg 
11.7.14 
0.4mg 
11.7.15 
4.5mg 
11.7.16 
4.8mg 
11.7.17 
2.4mg 
11.7.18 
2mg 
11.7.19 
<0.1mg 
11.7.20 
<0.1mg 
Figure 68: Separation tree of Cliona celata (RI 1-11) 
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 WE 2-20 Lyngbya sp. wet weight 200g 
Methanol:dichloromethane (3:1) 
 
WE 2-20 Extract 3.0785g 
C18 Column (75g) 
WE 2-20 .1 
<0.1mg 
 
20.2 
<0.1mg 
 
20.3 
257.3 mg 
20.4 
48.1 mg 
20.5 
70.4 mg 
20.6 
348.1 mg 
 
20.7 
158.9 mg 
 
20.8 
119.7 mg 
20.9 
239.3 mg 
20.10 
32.5 mg 
20.11 
8 mg 
20.12 
<0.1mg 
 
 LH-20 Column (150g) 
20.8.1 
 
20.8.2 20.8.3 
0.7 mg 
20.8.4 
7.6 mg 
20.8.5 
19.3 mg 
20.8.6 
26.1 mg 
20.8.7 
20.1 mg 
20.8.8 
14.8 mg 
20.8.9 
7.7 mg 
20.8.10 
3.2 mg 
20.8.11 
0.3 mg 
20.8.12 
0.3 mg 
20.8.13 
0.3 mg 
20.8.14 
0.6 mg 
20.8.15 
0.4 mg 
LH-20 Column 
(150g) 
 
20.7.1 
0.1mg 
 
20.7.2 
12.6mg 
20.7.3 
10.4mg 
20.7.4 
10.9mg 
20.7.5 
10.2mg 
20.7.6 
11mg 
20.7.7 
10.7mg 
20.7.8 
11.7mg 
20.7.9 
4.4mg 
20.7.10 
2.9mg 
20.7.11 
0.4mg 
20.7.12 
0.2mg 
20.7.13 
2.6mg 
20.7.14 
<0.1mg 
 
20.9.1 
2mg 
20.9.2 
19.5mg 
20.9.3 
11.5mg 
20.9.4 
11.6mg 
20.9.5 
23.8mg 
20.9.6 
24.2mg 
20.9.7 
16.1mg 
20.9.8 
11.4mg 
20.9.9 
13.5mg 
20.9.10 
19.3mg 
LH-20 Column (150g) 
20.9.11 
63.8mg 
20.9.12 
35mg 
20.9.13 
2.3mg 
20.9.14 
0.6mg 
Figure 69: Separation tree of Lyngbya sp.(WE 2-20) 
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Figure 70: Base peak chromatogram of RI 1-11 Cliona celata with mass spectra 
of metabolites of interest 
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Figure 71: Base peak chromatogram of RI 1-11.6.6 with mass spectra of 
metabolites of interest 
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Figure 72: Base peak chromatogram of WE 2-20 Lyngbya sp. with mass spectra 
of metabolites of interest 
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Figure 73: Base peak chromatogram of WE 2-20.7.3 with mass spectra of 
metabolites of interest 
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Figure 74: Base peak chromatogram of WE 2-20.8.7 with mass spectra of 
metabolites of interest 
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Figure 75: Base peak chromatogram of WE 2-20.9.3 with mass spectra of 
metabolites of interest 
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Figure 76: Base peak chromatogram of RI 2-13 Aplidium sp. with mass spectra 
of metabolites of interest 
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Figure 77: Base peak chromatogram of RI 2-14 Alcyonaria sp. with mass spectra 
of metabolites of interest 
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Figure 78: Base peak chromatogram of RI 2-17 Ircinia sp. (horny sponge) with 
mass spectra of the metabolite of interest  
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